SCHEMBL2239959

SCHEMBL2239959

c1ccc2c(Sc3ccc(Nc4nnc(-c5ccc6c(c5)OCO6)c5ccccc45)cc3)ccnc2c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.51
NPSR1 Q6W5P4 3/20 0.51
POLB P06746 1/20 0.51
GAA P10253 3/20 0.48
HSD17B10 Q99714 6/20 0.47
CYP1A2 P05177 5/20 0.47
CYP3A4 P08684 5/20 0.47
CYP2D6 P10635 5/20 0.47
MAPK1 P28482 5/20 0.47
TP53 P04637 4/20 0.47
CYP2C19 P33261 4/20 0.47
TSHR P16473 4/20 0.47
ALOX15 P16050 4/20 0.47
MEN1 O00255 4/20 0.47
KMT2A Q03164 4/20 0.47
CLK4 Q9HAZ1 4/20 0.47
ALDH1A1 P00352 3/20 0.47
USP2 O75604 3/20 0.47
LMNA P02545 3/20 0.47
NPC1 O15118 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3699709 0.93 MAPT (0.49) MAPTNPSR1POLBGAAHSD17B10
SCHEMBL15663418 0.91 MAPT (0.49) MAPTNPSR1POLBGAAHSD17B10
SCHEMBL3697300 0.89 MAPT (0.49) MAPTNPSR1POLBGAAHSD17B10
SCHEMBL15663303 0.84 MAPT (0.44) MAPTNPSR1POLBGAAHSD17B10
SCHEMBL15663504 0.84 MAPT (0.46) MAPTNPSR1POLBGAAHSD17B10
SCHEMBL2210377 0.84 ENPP3 (0.50) MAPTNPSR1POLBGAAHSD17B10
SCHEMBL15663807 0.82 KDR (0.53) MAPTNPSR1POLBGAAHSD17B10
SCHEMBL2982066 0.80 PDE10A (0.40) MAPTNPSR1POLBGAATP53
SCHEMBL15663306 0.77 KDR (0.39) MAPTNPSR1POLBGAATP53
SCHEMBL2206693 0.77 ENPP3 (0.47) MAPTNPSR1POLBGAAHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7981891-B2 Aurora kinase modulators and method of use AMGEN INC. (US) 2011-07-19 US claimed
US-20100280008-A1 AURORA KINASE MODULATORS AND METHOD OF USE AMGEN INC. (US) 2010-11-04 US claimed
EP-2137177-B1 AURORA KINASE MODULATORS AND METHOD OF USE AMGEN INC (US) 2014-05-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100280008-A1 AURORA KINASE MODULATORS AND METHOD OF USE AURKC, AURKA, CDK1 MAPT 1693/4885NPSR1 2810/4885POLB 1671/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.